Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy

Hormone Research

Volumn 53, Issue 4, 2000, Pages 200-206

  Eiholzer, Urs ^a   L'Allemand, Dagmar ^a   Van Der Sluis, Inge ^b   Steinert, Hans ^c   Gasser, Theo ^c   Ellis, Kenneth ^d  

^a Foundation Growth Puberty Adolescence Zurich   (Switzerland)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Body composition; Fat mass; Growth hormone therapy; Lean mass; Prader Labhart Willi syndrome; Prader Willi syndrome; Syndromal obesity

Indexed keywords

HUMAN GROWTH HORMONE;

ADOLESCENT; ARTICLE; BODY COMPOSITION; BODY FAT; CHILD; CLINICAL ARTICLE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; LEAN BODY WEIGHT; LONG TERM CARE; MALE; OBESITY; PHENOTYPE; PRADER WILLI SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0033759996     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000023567     Document Type: Article

References (35)

1. Energy expenditure and body composition in Prader-Willi syndrome
2. Prader-Willi syndrome
3. Prader Willi syndrome after age 15 years
4. Growth hormone improves body composition fat utilization, physical strength and agility in Prader-Willi syndrome: A controlled study
5. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably
6. Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance
7. Effect of growth hormone on height, weight, and body composition in Prader-Willi syndrome
8. Body composition studies in Prader-Willi syndrome: Effects of growth hormone therapy
9. Growth hormone normalises height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy
10. Nutritional management
11. Physical growth of Swiss children from birth to 20 years of age
12. Fat mass in infants and toddlers: Comparability of total body water, total body potassium, total body electrical conductivity, and dual-energy X-ray absorptiometry
13. Measuring body fatness in children and young adults: Comparison of bioelectric impedance analysis, total body electrical conductivity, and dual-energy X-ray absorptiometry
14. Determinants of body composition measured by dual-energy X-ray absorptiometry in Dutch children and adolescents
15. Body composition analysis by dual-energy X-ray absorptiometry in female diabetics differ between manufacturers
16. Comparisons between Hologic, Lunar and Norland dual-energy X-ray absorptiometers and other techniques used for whole-body soft tissue measurements
17. Pituitary evaluation and growth hormone treatment in Prader-Willi syndrome
18. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome
19. Body composition of a young, multiethnic female population
20. Body composition of a young, multiethnic, male population
21. One-year results of growth hormone treatment of short stature in Prader-Willi syndrome
22. Growth hormone treatment of obese women for 5 weeks: Effect on body composition and adipose tissue LPL activity
23. Persistent lipolytic effect of exogenous growth hormone during caloric restriction
24. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure
25. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults
26. Five years of growth hormone treatment in children with Prader-Willi syndrome. Swedish National Growth Hormone Advisory Group
27. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome
28. Treatment of obese diet-restricted subjects with growth hormone for 11 weeks: Effects on anabolism, lipolysis, and body composition
29. Comparative rapidity of response of height, limb muscle and limb fat to treatment with human growth hormone in patients with and without growth hormone deficiency
30. Magnetic resonance imaging evaluation of adipose tissue and muscle tissue mass in children with growth hormone (GH) deficiency, Turner's syndrome, and intrauterine growth retardation during the first year of treatment with GH
31. Guidelines for the use of growth hormone in children with short stature: A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society
32. Fat-free mass as a function of fat mass in children with Prader-Willi syndrome
33. Peculiar body composition in patients with Prader-Labhart-Willi syndrome
34. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients